Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized Open-label Study of MEDI-551 in Adults With Relapsed or Refractory DLBCL

NCT01453205 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT01453205
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01453205 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized Open-label Study of MEDI-551 in Adults With Relapsed or Refractory DLBCL
Lead sponsor
MedImmune LLC
Phase
Phase 2
Overall status
Completed
Start date
February 27, 2012
Completion date
July 11, 2016
Enrollment
187 (actual)
Sites
81

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma